Daily Bio News Summary — 2026-09-06: Ionis FDA Win, Novartis CAR-T Deaths, and Biotech IPO Momentum

Today’s Harvest: 27 Articles from 10 Sources

Today’s biopharma news harvest captured27articles across10sources — Endpoints News led with14articles, followed by STAT News (6), Reuters Biopharma (3), Fierce Pharma (2), Fierce Biotech (1), and PR Newswire FDA (1). The collection spans FDA regulatory actions, major licensing deals, clinical trial setbacks, and fresh biotech funding rounds.

FDA Activity: Alexander Disease Win and Foreign Data Scrutiny

The biggest regulatory news today is Ionis Pharmaceuticals receiving FDA approval for zilganersen, its Alexander disease drug and the company’s first solo neurology approval (Endpoints News, 2026-09-04). This marks a significant milestone for the RNA-targeted therapeutics company.

In a separate but notable FDA development, a CBER official overruled the review team’s rejection of Replimune’s melanoma drug, raising questions about internal decision-making processes at the agency (Endpoints News, 2026-09-03). Meanwhile, FDA officials are signaling enhanced scrutiny of foreign clinical trial data, coinciding with the rise of China-based biopharma companies (Endpoints News, 2026-09-03).

Clinical Setbacks: Novartis CAR-T Deaths

Two articles cover the Novartis CAR-T cell therapy trial deaths that have forced a reckoning in the autoimmune disease space. Novartis halted the trial after patient deaths, raising fundamental questions about acceptable risk levels in CAR-T treatments for autoimmune conditions (Endpoints News, 2026-09-03). This is a significant development as CAR-T therapies have been increasingly explored beyond oncology.

Deal-Making: GSK, Merck, and Pfizer Active

GSK licensed HUTCHMED’s dual-action KRAS/EGFR cancer drug for $110 million upfront (Endpoints News, 2026-09-03), while Merck’s M&A chief signaled increased deal flow as the Keytruda patent cliff approaches (Endpoints News, 2026-09-04). Pfizer offloaded a discontinued Seagen antibody-drug conjugate to Medicus Pharma in a deal valued at up to $1 billion (Fierce Biotech, 2026-09-03).

Novartis also signed a major drug delivery technology deal with Alteogen, and Cellares implemented further workforce reductions (Endpoints News, 2026-09-04).

Funding and IPOs: ADARx Leads the Way

ADARx Pharmaceuticals, allied with AbbVie, filed for an IPO with three RNA-based drugs in the clinic (Endpoints News, 2026-09-04). NeuShen Therapeutics, founded by former I-Mab chief Joan Shen, raised over $80 million for three brain-health drug candidates (Endpoints News, 2026-09-04). Superluminal Medicines secured $60 million for its genetic obesity drug Phase 1 (Endpoints News, 2026-09-03).

Workforce Changes: Arsenal Bio Pivots

Arsenal Biosciences cut the majority of its staff as it pivots from ex vivo to in vivo CAR-T cell therapy (Endpoints News, 2026-09-02). Lindus Health, backed by Peter Thiel, sold its CRO arm to focus on hunting external drug assets (Endpoints News, 2026-09-04).

What This Batch Is Not Telling Us

Today’s harvest is notably light on AI-in-bio news, IPO pricing (ADARx filed but no pricing yet), and Phase 3 readouts. The collection also lacks coverage of European regulatory actions and Asia-Pacific deal-making beyond the HUTCHMED-GSK deal.

Reading Order

For limited-time readers, prioritize:

1. Ionis FDA approval for Alexander disease — a genuine milestone for RNA therapeutics
2. Novartis CAR-T trial deaths — safety signal with industry-wide implications
3. ADARx IPO filing — tests public market appetite for RNA therapeutics
4. GSK-HUTCHMED licensing deal — validates KRAS/EGFR dual-targeting approach
5. FDA foreign data scrutiny — policy shift affecting China-origin clinical programs

Sources

All articles sourced from the daily biopharma news harvest across BioSpace, Fierce Pharma, Fierce Biotech, STAT News, Endpoints News, FDA Newsroom, BioPharma Dive, MedCity News, Reuters Biopharma, Pharmaphorum, and PR Newswire FDA.